Questcor to Report Second Quarter Financial Results on July 30, 2013

     Questcor to Report Second Quarter Financial Results on July 30, 2013

PR Newswire

ANAHEIM, Calif., July 12, 2013

ANAHEIM, Calif., July 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc.
(Nasdaq: QCOR) today announced that it will releasesecond quarter 2013
financial results on Tuesday, July 30, 2013 after the close of the U.S.
financial markets. The Company will host a conference call and slide
presentation via webcast on Tuesday, July 30, 2013 at 4:30 p.m. Eastern /
1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as
current corporate developments..

The call can be accessed in the following ways:

  oBy webcast: At Questcor's investor relations website,
    http://ir.questcor.com/.
  oBy telephone: For both "listen-only" participants and those participants
    who wish to take part in the question-and-answer portion of the call, the
    dial-in number in the U.S. is (877) 354-0215. For participants outside the
    U.S., the dial-in number is (253) 237-1173.
  oBy audio replay: A replay of the conference call will be available for
    seven business days following conclusion of the live call. The telephone
    dial-in number for U.S. participants is (855) 859-2056. For participants
    outside the U.S., the replay dial-in number is (404) 537-3406. The replay
    access code for all callers is 16591264.

About Questcor


Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor also provides specialty contract
manufacturing services to the global pharmaceutical industry through its
wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P.
Acthar® Gel (repository corticotropin injection), an injectable drug that is
approved by the FDA for the treatment of 19 indications. Of these 19
indications, Questcor currently generates substantially all of its net sales
from the following on-label indications: the treatment of proteinuria in the
nephrotic syndrome of the idiopathic type, or NS, the treatment of acute
exacerbations of multiple sclerosis, or MS, in adults, the treatment of
infantile spasms, or IS, in infants and children under two years of age, and
the treatment of certain rheumatology related conditions. With respect to
nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a
remission of proteinuria in the nephrotic syndrome without uremia of the
idiopathic type or that due to lupus erythematosus." Questcor has announced
its intent to initiate a pilot commercialization effort for Acthar for the
treatment of respiratory manifestations of symptomatic sarcoidosis. The FDA
approved package insert for Acthar includes "symptomatic sarcoidosis" under
the heading "Respiratory Diseases". Questcor is also exploring the
possibility of developing markets for other on-label indications and the
possibility of pursuing FDA approval of additional indications not currently
on the Acthar label where there is high unmet medical need. Questcor also has
agreed to acquire certain international rights for Synacthen® (tetracosactide)
and Synacthen Depot®, and has licensed the right to develop and seek FDA
approval for these products in the United States. For more information about
Questcor, please visit www.questcor.com.



SOURCE Questcor Pharmaceuticals, Inc.

Website: http://www.questcor.com
Contact: EVC Group. Gregory Gin, 646-445-4801, or Patty Eisenhaur,
951-316-0577; or Janine McCargo, 646-688-0425